The Adverse Event Unit (AEU): A novel metric to measure the burden of treatment adverse events

PLoS One. 2022 Feb 17;17(2):e0262109. doi: 10.1371/journal.pone.0262109. eCollection 2022.

Abstract

Objective: To design a physician and patient derived tool, the Adverse Event Unit (AEU), akin to currency (e.g. U.S. Dollar), to improve AE burden measurement independent of any particular disease or medication class.

Patients/methods: A Research Electronic Data Capture (REDCap) online survey was administered to United States physicians with board certification or board eligibility in general neurology, subspecialty neurology, primary care internal medicine or family medicine, subspecialty internal medicine, general pediatrics, and subspecialty pediatrics. Physicians assigned value to 73 AE categories chosen from the Common Terminology Criteria of Adverse Events (CTCAE) relevant to neurologic disorder treatments. An online forced choice survey was administered to non-physician, potential patients, through Amazon Mechanical Turk (MTurK) to weight the severity of the same AE categories. Physician and non-physician data was combined to assign value to the AEU. Surveys completed between 1/2017 and 3/2019.

Results: 363 physicians rated the 73 AE categories derived from CTCAE. 660 non-physicians completed forced choice experiments comparing AEs. The AEU provides 0-10, weighted values for the AE categories studied that differ from the ordinal 1-4 CTCAE scale. For example, CTCAE severe diabetes (category 4) is assigned an AEU score of 9. Although non-physician input changed physician assigned AEU values, there was general agreement among physicians and non-physicians about severity of AEs.

Conclusion: The AEU has promise to be a useful, practical tool to add precision to AE burden measurement in the clinic and in comparative efficacy research with neurology patients. AEU utility will be assessed in planned comparative efficacy clinical trials.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Adverse Drug Reaction Reporting Systems / statistics & numerical data*
  • Drug-Related Side Effects and Adverse Reactions / etiology
  • Drug-Related Side Effects and Adverse Reactions / pathology*
  • Drug-Related Side Effects and Adverse Reactions / therapy
  • Drugs, Investigational / adverse effects*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nervous System Diseases / drug therapy*
  • Nervous System Diseases / pathology
  • Patient Reported Outcome Measures*
  • Physicians / statistics & numerical data*
  • Surveys and Questionnaires

Substances

  • Drugs, Investigational

Grants and funding

This study was supported by American Academy of Neurology, American Brain Foundation, Myasthenia Gravis Foundation of America 2016-2019 (Grant No. 2016-0231) awarded to MH. The funder did not play role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.